Status:
COMPLETED
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Lead Sponsor:
Jonathan A. Bernstein, MD
Conditions:
Atopic Dermatitis
Eczema
Eligibility:
All Genders
19-75 years
Phase:
PHASE4
Brief Summary
The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis
Detailed Description
The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/ skin strips will...
Eligibility Criteria
Inclusion
- history of adult onset atopic dermatitis
Exclusion
- \-
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04358224
Start Date
September 1 2020
End Date
November 18 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bernstein Clinical Research Center
Cincinnati, Ohio, United States, 45231